Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
989 results
- APROPOSIndependent statistical analysis of A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01907269).
- ARICAIndependent statistical analysis of AdheRence to Inhaled Corticosteroids in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03769519).
- ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection: Complete Statistical AnalysisIndependent statistical analysis of ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I: Complete Statistical AnalysisIndependent statistical analysis of Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II: Complete Statistical AnalysisIndependent statistical analysis of Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II: primary endpoint results, effect estimate with confidence interval, sample-size…
- ASIA MRI ICDIndependent statistical analysis of A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia: Complete Statistical AnalysisIndependent statistical analysis of Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO): Complete Statistical AnalysisIndependent statistical analysis of Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents: Complete Statistical AnalysisIndependent statistical analysis of Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying…
- ASSISTIndependent statistical analysis of AsseSSing Impact in pSoriatic Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05171270).
- Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00826007).
- ASTRAL-5Independent statistical analysis of Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection: primary endpoint results,…
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site: primary endpoint results, effect estimate with…
- Atezolizumab Immunotherapy in Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab Immunotherapy in Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03102242).
- ATHENA-1Independent statistical analysis of A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04339426).
- Attain Success Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Attain Success Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00990964).
- Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists: Complete Statistical AnalysisIndependent statistical analysis of Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04196777).
- AURIONIndependent statistical analysis of Aurinia Early Urinary Protein Reduction Predicts Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02949973).
- Autologous and Allogeneic Transplant for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous and Allogeneic Transplant for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00802113).
- Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene: Complete Statistical AnalysisIndependent statistical analysis of Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene: primary endpoint results, effect estimate…
- Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma (BMT CTN 0202): Complete Statistical AnalysisIndependent statistical analysis of Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009): Complete Statistical AnalysisIndependent statistical analysis of Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer…
- Automated Mobile Contingency Management for Smoking Cessation: A Pilot RCT (SCC PREVAILgo): Complete Statistical AnalysisIndependent statistical analysis of Automated Mobile Contingency Management for Smoking Cessation: A Pilot RCT (SCC PREVAILgo): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02698891).
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: Complete Statistical AnalysisIndependent statistical analysis of B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03020537).
- Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02223338).
- Barre Exercise in Parkinson’s: Complete Statistical AnalysisIndependent statistical analysis of Barre Exercise in Parkinson's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06203990).
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).
- BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326495).
- BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BE ACTIVE 2Independent statistical analysis of A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BEACONIndependent statistical analysis of HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEAGLE R21Independent statistical analysis of Behavioral Economics Applications to Geriatrics Leveraging EHRs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03704389).
- Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01351766).
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00401817).
- Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).